• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Reva, Biotronik tout safety data for their drug-eluting bioresorbable scaffolds

November 1, 2017 By Sarah Faulkner

Reva Medical, BiotronikDespite the safety concerns plaguing Abbott‘s (NYSE:ABT) Absorb device, companies developing bioresorbable scaffolds are not discouraged. This week at the annual Transcatheter Cardiovascular Therapeutics Conference in Denver, a number of companies touted the safety data coming from clinical trials of their products.

Among them were Reva Medical (ASX:RVA) and Biotronik – here’s an overview of that data.

Reva Medical’s Fantom coronary scaffold

The San Diego, Calif.-based company reported an interim data set of 125 patients that the company followed for two years and revealed plans for its next-gen device, called Fantom Encore.

Reva said that the interim data set included a 5.6% rate of major adverse cardiac events and one very late scaffold thrombosis event. The company has previously reported a 4.2% major adverse cardiac event rate after 1 year, so Reva touted this two-year data set as demonstrating a sustained safety profile for its sirolimus-eluting Fantom device.

A 25-patient subgroup also underwent angiographic imaging to determine late lumen loss after two years, Reva said. The company found that its device produced a final in-scaffold late lumen loss of 0.25 mm.

“This preliminary data set from the Fantom II trial provides physicians with an early look at two-year clinical results for the Fantom scaffold,” trial investigator Dr. Ricardo Costa said in prepared remarks. “The low MACE rate and inscaffold late lumen loss measurement are encouraging as they demonstrate sustained safety and performance of Fantom out to 24 months in this group of patients.”

At TCT, Reva also unveiled plans for a scaffold with struts that are 95-microns thick.

“Reva’s announcement of 95 micron strut thickness for Fantom Encore in the 2.5 mm diameter is a promising development for bioresorbable scaffold technology,” Dr. James Hermiller of the Heart Center of Indiana added. “Bioresorbable scaffolds have the potential to offer patients short term benefits of metallic stents without the long-term complications. Thinner struts have been associated with improved deliverability and vessel healing.”

Biotronik’s Magmaris limus-eluting scaffold

Biotronik touted pooled 12-month data from its Biosolve-II and Biosolve-III trials, reporting a continuous absence of late definite or probable scaffold thrombosis with its Magmaris limus-eluting resorbable magnesium scaffold.

“We now have another set of evidence where even when pooling Biosolve-II and -III data, Magmaris shows zero percent definite and probable scaffold thrombosis for up to 12 months in clinical trials,” coordinating clinical investigator Dr. Michael Haude said in prepared remarks. “This adds to our understanding that approximately 95 percent of the magnesium scaffold is being resorbed within 12 months.”

Angiographic follow-up of 97 patients between the two trials showed in-segment late lumen loss of 0.25mm (+/-0.31mm) after one year. The company also reported a pooled target lesion failure rate of 3.3% at 12 months, comparable to second-gen drug-eluting stents.

“At a time when questions have been raised about poly-L-lactide (PLLA) scaffolds, we are pleased to once again report safe and efficacious results for Magmaris,” Alexander Uhl, VP of marketing for Biotronik’s vascular intervention business, added. “These data reiterate that magnesium-based resorbable technology is entirely different in both mode of action and clinical outcomes to PLLA-based bioresorbable scaffolds (BRS). We at Biotronik remain committed to vessel restoration therapy based on magnesium technology.”

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals, Vascular Tagged With: abbott, Biotronik, Reva Medical

IN CASE YOU MISSED IT

  • FDA approves first targeted infusion therapy for HER2-low breast cancer
  • Abbott, WeightWatchers partner on diabetes care
  • Insulet up on Q2 sales beat, raised full-year guidance
  • Aptar acquires Orbital dry powder inhaler license
  • Tandem sinks on Q2 misses, slashed sales guidance

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS